When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

Additional support came from Abingworth, Invus, Tenmile, Vida Ventures, Vinyanshu Ventures and Willett Advisors.

Pierre Fabre Labs expands R&D portfolio; announces acquisition of the worldwide rights for PFL-721 & PFL-241: Castres, France Wednesday, June 18, 2025, 11:00 Hrs [IST] Pierre Fabr ...

It was meant to be a routine rocket launch to resupply the International Space Station, the fifth mission sent with that objective, and all witnesses expected yet another successful take-off of the ...

Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Late last month, Firefly announced that Northrop Grumman has invested $50 million into accelerating the development of the ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

The waxing gibbous moon will shine close to the red star Antares in the constellation Scorpius on the night of June 9.

Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. Antares is a spin ...

Antares Therapeutics has launched with $177 million in series A financing and a staff already at full speed, according to CEO Adam Friedman. The company is a spin-off of Scorpion Therapeutics ...

On the evening of June 9, skywatchers will be treated to a beautiful cosmic pairing. The waxing gibbous moon will glow close ...